Organization
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3 abstracts
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: NRG Oncology Statistics and Data Management Center, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, University Hospitals Seidman Cancer Center, Cleveland, OH, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Radiology School of Medicine, University of California, San Francisco, San Francisco, CA,
Abstract
Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Org: The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, BC Cancer Agency, Vancouver, Canada, City of Hope, Duarte, CA, Barts Cancer Institute, London, United Kingdom,
Abstract
Sexual dysfunction in patients with cancer: Results from the CLARIFY project.Org: Instituto de Investigacion Sanitaria Puerta de Hierro - Segovia de Arana, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda, Spain, Hospital Universitario Puerta de Hierro, Madrid, Majadahonda., Spain, Instituto Investigacion Sanitaria Puerta de Hierro-Segovia de Arana,